Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
about
Consensus on anti-platelet therapy in peripheral arterial disease: saving lives and limbsCilostazol for prevention of thrombosis and restenosis after intracoronary stentingPharmacology and clinical use of bivalirudin.Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients.Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options.Eptifibatide: The evidence for its role in the management of acute coronary syndromes.Heparin in interventional radiology: a therapy in evolutionOral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.Platelet biology and implications for antiplatelet therapy in atherothrombotic disease.Intracranial angioplasty and stent placement after stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) trial: present state and future considerations.Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban.Use of antiplatelet inhibitors in peripheral vascular interventions.Emerging oral antiplatelet therapies for acute coronary syndromes.Comparison of anti-Xa activity after a single intravenous bolus of low-dose enoxaparin in patients with and without end-stage renal disease.Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention.First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.The Angio-Seal arterial closure device for early ambulation after elective percutaneous coronary intervention in patients receiving low-dose enoxaparin.Proceedings of the TCT: questions surround antithrombotic therapy in coronary DES implantation.Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
P2860
Q28166706-0A0EE61B-86DF-41B7-880A-A722853B933EQ28189483-9D0D6F86-BECA-48FD-86C3-3498CC9AE2CDQ33342507-094B8A93-CB4F-4914-88CA-FFD859A63D3AQ33342836-F51E0E37-DFCF-416C-81A7-8F22A5F55796Q33369119-58CA2B2F-043E-4FB1-976E-B2EB0B799E6FQ33391279-A5C1005D-B04F-4BBA-AD75-CAFF1BAF0267Q33394179-6793587E-7835-4166-8121-8BDE0E0CE392Q35797491-B0019474-3684-499B-A03E-EDD1FBC74F03Q35826954-E5F9A3A2-2F31-458F-A1CA-DDBAF82E42E5Q36131116-0574B749-2105-4796-BFBA-5F61A732634AQ36787291-46C3C96E-BBAA-4111-8E6E-F88E11EE02A0Q37766688-A40F06B9-30B9-41B2-B22C-1D1B9A98F91FQ37976465-3668172D-CCF1-440C-93DF-BB0AB0611820Q39814692-34CE124E-54E8-46D3-B518-48E499F84616Q42118681-E67FAFD4-886D-4FF7-AF1E-D4A492BDBEA5Q42822406-485F8B92-CEB6-481B-8329-9AB1365A0424Q43166177-C962AE7B-9C6C-457C-BA40-28CBCBA938BFQ45022889-65392932-871A-4FB0-8131-135A5E8E1A8CQ45302042-A3A0906D-273E-4641-9C69-5EFF3E73F0CBQ46334556-F879A90A-4F39-4EFD-AB53-4C70F547B422Q51192882-CF8A228F-CA4F-4EB7-A2A8-3B7A8C01A3B2Q53292171-F1A9B9CA-A2C8-4B61-AAC1-AC49F661B6F7
P2860
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@ast
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@en
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@nl
type
label
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@ast
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@en
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@nl
prefLabel
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@ast
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@en
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@nl
P2093
P1433
P1476
Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
@en
P2093
P304
P356
10.1378/CHEST.119.1_SUPPL.321S
P407
P433
P577
2001-01-01T00:00:00Z